Relationship Between Great Toe Strength And Symptoms of Chemotherapy-Induced Peripheral Ne
Great Toe Strength (GTS) is a potential clinical biomarker that has been associated with functional mobility and health; Additionally, GTS has been identified in the literature as one of the early symptoms of chemotherapy-induced peripheral neuropathy (CIPN). The purpose of this research study is to evaluate GTS in ind
| Condition(s) | Chemotherapy-induced Peripheral Neuropathy (CIPN), Healthy |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Great Toe Strength (GTS) is a potential clinical biomarker that has been associated with functional mobility and health; Additionally, GTS has been identified in the literature as one of the early symptoms of chemotherapy-induced peripheral neuropathy (CIPN). The purpose of this research study is to evaluate GTS in individuals with CIPN and healthy adults using ToeScale and see how it relates to nerve issues from chemotherapy. Additionally, we aim to assess the usability of the novel GTS assessment device, ToeScale among the participants. As a part of this study visit, you will complete some questionnaires followed by GTS and balance and gait assessments. |
| Who can participate | Eligibility Criteria for Chemotherapy-Induced Peripheral Neuropathy (CIPN) group: Inclusion Criteria: * At least 18 years of old with the ability to independently raise and low (extend or flex) the great toe * Able to consent and complete questionnaires in English independently and have normal to corrected vision (self-reported) * Within 3 - 6 months of starting chemotherapy and a confirmed diagnosis of CIPN using the current clinical reference standard of Nerve conduction study. Exclusion Criteria: * Comorbidities including but not limited to diabetes, arthritis, hypertension, thyroid disease, and heart disease, . that have been reported to be associated with the incidence of peripheral neuropathy and/or progression of CIPN. * Toe deformities or impairments not caused by CIPN (including b |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | University of Florida |
| Locations | Gainesville, Florida, United States |
| Start date | 2025-08-05 |
| NCT ID | NCT07009717 |
| Official listing | https://clinicaltrials.gov/study/NCT07009717 |